肉瘤样肾细胞癌辅助治疗:ECOG-ACRIN E2805事后分析
该研究基于随机双盲III期试验E2805中171例肉瘤样肾细胞癌患者,比较舒尼替尼、索拉非尼与安慰剂辅助治疗的效果。结果显示,舒尼替尼或索拉非尼均未改善无病生存期或总生存期。
要点
- 肉瘤样肾细胞癌患者中,辅助舒尼替尼或索拉非尼未改善DFS。
- 舒尼替尼对比安慰剂DFS的HR为0.74(95%CI 0.45-1.20)。
- 索拉非尼对比安慰剂DFS的HR为0.82(95%CI 0.53-1.28)。
核心结论
- 辅助舒尼替尼或索拉非尼未改善肉瘤样肾细胞癌患者的无病生存期或总生存期。
研究设计与样本
- E2805为随机双盲III期试验,2006至2010年纳入1943例肾细胞癌患者,辅助治疗至多1年。
- 本分析纳入其中171例(8.8%)肉瘤样肾细胞癌患者,舒尼替尼组52例、索拉非尼组58例、安慰剂组61例。
主要发现
- 舒尼替尼、索拉非尼和安慰剂组5年无病生存率分别为33.6%、36.0%和27.8%。
- 舒尼替尼对比安慰剂DFS的HR为0.74(95%CI 0.45-1.20),索拉非尼对比安慰剂HR为0.82(95%CI 0.53-1.28)。
- 发生转移的患者中49%首先转移至肺,30%至淋巴结,13%至肝脏;肾床局部复发率分别为16%、29%和18%。
临床怎么用
- 对于肉瘤样肾细胞癌患者,不推荐使用辅助舒尼替尼或索拉非尼以改善生存。
局限性
- 本研究为事后分析,肉瘤样肾细胞癌亚组样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To study the effects of adjuvant therapy in patients with sarcomatoid renal cell carcinoma (sRCC) enrolled in the randomised phase III clinical trial E2805. PATIENTS AND METHODS: The original trial (E2805) was a randomised, double-blinded phase III clinical trial comparing outcomes in 1943 patients with RCC accrued between 2006 and 2010 and treated with up to 1 year of adjuvant placebo, sunitinib, or sorafenib. The present study analyses the cohort of patients with sRCC that participated in E2805. RESULTS: A total of 171 patients (8.8%) had sarcomatoid features. Of these, 52 patients received sunitinib, 58 received sorafenib, and 61 received placebo. Most patients were pT3-4 (71.1%, 63.7%, and 70.5%, respectively); 17.3%, 19.0%, and 27.9% had pathologically positive lymph nodes; and 59.6%, 62.1%, and 62.3% of the patients were University of California Los Angeles (UCLA) Integrated Staging System (UISS) very-high risk. In 49% of patients with subsequent development of metastatic disease, recurrence occurred in the lung, followed by 30% in the lymph nodes, and 13% in the liver. There was a high local recurrence rate in the renal bed (16%, 29%, and 18%, respectively). The 5-year disease-free survival (DFS) rates were 33.6%, 36.0%, and 27.8%, for sunitinib, sorafenib and placebo, respectively (hazard ratio [HR] 0.74, 95% confidence interval [CI] 0.45-1.20 for sunitinib vs placebo, and HR 0.82, 95% CI 0.53-1.28 for sorafenib vs placebo). CONCLUSIONS: Adjuvant therapy with sunitinib or sorafenib did not show an improvement in DFS or OS in patients with sRCC.
引用
- Karam JA, Puligandla M, Flaherty KT, et al. Adjuvant therapy in patients with sarcomatoid renal cell carcinoma: post hoc analysis from Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN) E2805. BJU Int. 2021. PMID: 34480522. doi:10.1111/bju.15587
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。